 iTeos Therapeutics NASDAQ: ITOS and GlaxoSmithKline plc NYSE: GSK have agreed to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody. Under the terms of the collaboration agreement, iTeos will receive an upfront payment of 625 million. 